MedTrace Logo

Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years

NCT00353184 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-02-24

No results posted yet for this study

Summary

Oral montelukast is helpful in chronic asthma. The purpose of this pediatric study was to investigate whether the addition of oral montelukast to standard therapy for acute asthma exacerbations results in further improvement in breathing function over three hours.

Conditions

Interventions

DRUG

Montelukast 5-mg orally added to standard therapy

Sponsors & Collaborators

  • American Academy of Pediatrics

    collaborator OTHER

  • Ambulatory Pediatric Association

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Kyle A Nelson, MD · Physician in Division of Pediatric Emergency Medicine at Washington University School of Medicine in St. Louis

  • David M Jaffe, MD · Senior Advisor for Study, Division Director for Pediatric Emergency Medicine at Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2004-10-31
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353184 on ClinicalTrials.gov